ArchiveMigraine is a common and chronic disease that is characterized by episodic headache that can cause disability, accompanied by aura and other symptoms. The etiology is relatively unknown, and four rare related genes have been identified. The pathogenesis of migraine may be related to spreading depolarization, which probably causes aura and initiates activation of trigeminal pain pathway, ultimately triggering headache. Vasodilation is possibly a secondary phenomenon. The treatment of migraine varies according to the severity of the attack. Calcitonin gene related peptide (CGRP) receptor antagonists and selective 5-hydroxytryptamine 1F receptor agonist are expected to be effective in acute phase. Monoclonal antibodies targeting CGRP pathways and receptor antagonists are expected to prevent migraine because of their good efficacy and tolerance. Intramuscular injection of botulinum toxin A can be a treatment option for chronic migraine. The emergence of new medications indicates the bright future for migraine management.
Migraine is a common neurological disease, and its pathogenesis has not been clearly defined. It is believed that migraine as a complex hereditary disease is caused by the combination of genetic factors and environmental factors. At present, the genetic research of migraine has only obtained a unified understanding in several single gene inherited migraine. In recent years, the whole genome association analysis technique has been applied to the genetic research of migraine and a lot of achievements have been obtained. Migraine candidate genes have also been replicated in some studies. This article reviewed the research progress in genetic of migraine, in order to provide reference for further improving the diagnosis and treatment strategies of migraine.
Headache is a common neurological disorder. Among them, primary headache is more common, and seriously affects the quality of life of patients. This article tracked the progress on western medicine treatment of primary headache, combined the unique understanding of traditional Chinese medicine (TCM) on the diagnosis and treatment of headache, expounded the clinical advantages of TCM and western medicine in the treatment of headache, and looked forward to the development prospects of integrative TCM and western medicine in the treatment of headache.
Primary trigeminal neuralgia (PTN) is one of the common causes of head and facial pain in clinical practice. The etiology and pathogenesis of PTN have not been clearly defined. Although there are many treatment methods for PTN, but there is a lack of durable and effective treatment. Drug therapy is the first option of PTN, but the long-term efficacy is poor. For the patients who fail to respond to drug therapy or can not tolerate the side effects of drugs, surgery is another option, including microvascular decompression, partial trigeminal rhizotomy, percutaneous rhizotomy on the Gasserian ganglion, peripheral branch surgery of the trigeminal nerve, and electrical nerve stimulation. For patients who fail to respond to medical treatment and can not tolerate surgery, stereotactic radiosurgery can also be selected, for example, gamma knife and cyberknife. This article reviewed the treatment progress on PTN, in order to provide clinical reference for clinical practice.
To evaluate the protective effects and mechanism of mesalazine on ethanol induced gastric ulcer (GU) in rats.
Male SD rats were randomly divided into control group, ulcer group, omeprazole+ulcer group and mesalazine+ulcer group, with 10 rats in each group. GU was caused by oral administration of absolute ethanol (5 ml/kg) in rats. Omeprazole group and mesalazine group took omeprazole (20 mg/kg) or mesalazine (50 mg/kg) orally one hour before taking ethanol, respectively. One hour after ethanol treatment, the ulcer area, histopathology, lipid peroxidation, antioxidant enzymes and phosphorylation of nuclear factor (NF)-κB were observed.
Mesalazine pretreatment significantly decreased alcohol-induced GU, hemorrhage, hyperemia, and epithelial cell loss in the gastric mucosa. Mesalazine pretreatment reduced the level of malondialdehyde and increased total glutathione and superoxide dismutase in gastric tissues. In addition, it increased the expression levels of cyclooxygenase-1 and prostaglandin (PG)E2, and decreased the phosphorylation of NF-κB.
Mesalazine could effectively inhibit ethanol induced acute gastric injury by preventing oxidative damage, stimulating PGE2 production, and inhibiting NF-κB activation.
To investigate the effects of wogonin (Wog) on knee osteoarthritis (KOA) in rats by regulating nuclear factor (NF)-erythroid 2-related factor (Nrf2)/Toll like receptor 4 (TLR4)/NF-κB signaling pathway.
SD rats were randomly divided into normal group, model group, Wog low, medium and high dose (10, 30 and 90 mg/kg) groups, and positive control group (celecoxib, 24 mg/kg), with 10 rats in each group. KOA model was established by gavage of papain for 28 days. The mechanical and cold pain thresholds, pathological changes of cartilage, cell apoptosis, inflammatory factors, oxidative stress and protein expression levels were detected.
At postoperative D7, D14, D21, and D28, compared with the model group, the mechanical pain threshold and cold pain threshold of Wog medium and high dose groups and positive control group were significantly increased. Pathological damage of cartilage was significantly improved. Cell apoptosis rate, interleukin (IL)-6, IL-1β, tumor necrosis factor (TNF)-α, malondialdehyde, caspase-3, caspase-9, matrix metalloproteinase (MMP)-1, MMP-13, TLR4 protein level and the ratio of nuclear/total NF-κB p65 protein were significantly decreased. The activities of superoxide dismutase, glutathione peroxidase, Nrf2 and heme oxygenase-1 protein were significantly increased (P<0.01).
The mechanism of Wog reducing inflammatory damage in KOA rats may be related to upregulating Nrf2 expression and inhibiting TLR4/NF-κB activation.
To analyze the effect of Jianpi Qinghua decoction on islet cell differentiation in obese mice induced by high fat diet.
Six-week-old male C57BL/6 mice were randomly divided into normal group and high fat diet group after adaptive feeding for 1 week. After successful modeling, the high-fat group was randomly divided into model group and Jianpi Qinghua decoction group. After 6 weeks of intervention, body mass, fasting blood glucose (FBG), fasting insulin (FINS), glucose tolerance and lipid metabolism indexes of mice in each group were measured. Hematoxylineosin staining was used to observe the morphology and structure of pancreatic tissue. Immunofluorescence co-staining was used to observe the quantity and distribution of α cells, β cells and progenitor cell marker neurogenin (Ngn)3.
At the 5th week, the body weight of the high fat group was significantly increased compared with the normal group (P<0.01), and the body weight of the Jianpi Qinghua decoction group was decreased compared with the model group (P<0.05). After 30 min of glucose injection, blood glucose of the model group was significantly higher than that of the normal group (P<0.01). After 30, 60, 90 and 120 min of glucose injection, the blood glucose level and area under the curve of Jianpi Qinghua decoction group were significantly decreased compared with model group (P<0.01). FINS levels in Jianpi Qinghua decoction group were significantly decreased (P<0.01). The levels of serum cholesterol and triacylglycerol in Jianpi Qinghua decoction group were lower than those in model group (P<0.01). Fluorescence co-staining showed that β-cell and α-cell in Jianpi Qinghua decoction group increased significantly, and Ngn3, a marker of β-cell dedifferentiation and progenitor cell, was significantly decreased.
Jianpi Qinghua decoction can effectively reduce the levels of blood glucose, blood lipid and insulin in obese mice induced by high fat diet, which may be related to reversing the dedifferentiation of pancreatic β cells.
To investigate the effect of flurbiprofen axetil on hypoxia/reoxygenation (H/R)-induced neuronal injury and its regulatory mechanism.
Neuronal injury model was induced by H/R. Cell survival rate was detected by cell counting kit-8. The apoptosis rate was detected by flow cytometry. The neuronal injury was observed by transmission electron microscopy. The expression of oxidative stress and inflammatory factors were detected by enzyme linked immunosorbent assay. The protein level of the pathway was detected by western blotting (WB).
Compared with the control group, the neurons in the H/R group were severely damaged, the neuronal survival rate [(40.51±4.03)% vs 100%] was reduced, the apoptosis rate [(66.48±6.83)% vs (1.03±0.18)%] and the oxidative stress and inflammatory response were increased, and the Akt/GSK-3β/Nrf2/HO-1 signaling pathway was activated (P<0.01). Flurbiprofen axetil can alleviate H/R-induced neuronal injury, elevated neuronal survival rate [(73.36±7.08)% vs (40.51±4.03)%], reduce cell apoptosis rate [(32.27±3.45)% vs (66.48±6.83)%], and inhibit oxidative stress, inflammatory response and the Akt/GSK-3β/Nrf2/HO-1 signaling pathway (P<0.01).
Flurbiprofen axetil may protect neurons from H/R-induced injury by promoting the activation of oxidative stress pathway.
To explore the therapeutic effect of balancing cupping combined with ear-tip bloodletting on pruritus of chronic kidney disease.
A total of 60 patients with stage 4 to 5 chronic kidney disease with pruritus who treated in the department of nephrology, Jiangsu Hospital of Traditional Chinese Medicine from October 2020 to April 2021 were selected. The patients were randomly divided into control group and experimental group, and 30 cases each group. The control group was treated with conventional treatment and nursing, and the experimental group was treated with balanced cupping combined with ear-tip bloodletting on the basis of the control group. Evaluate the intervention effect with the uremic skin itching score as the primary efficacy indicator and the quality of life scale score as the secondary efficacy indicator.
After treatment, the total score and various scores of uremic skin itching score in both groups decreased compared to before treatment (P<0.05), and the improvement of symptoms and signs, sleep, and total score in the experimental group was better than that in the control group (P<0.05). The total score and various scores of life scales in both groups decreased compared to before treatment (P<0.05), and the improvement degree of the experimental group is better than that of the control group (P<0.05). No adverse reactions were observed during the treatment period.
On the basis of routine treatment and skin nursing, the combination of balanced cupping and ear-tip bloodletting can improve the pruritus of chronic kidney disease and the quality of life of patients.
To rapidly evaluate the efficacy, safety and economy of palonosetron in the prevention of chemotherapy-induced nausea and vomiting (CINV), so as to provide evidence-based support for clinical drug use.
By retrieving several major Chinese and English database, HTA reports, systematic reviews/meta-analysis and pharmacoeconomic studies about palonosetron in the prevention of CINV were included. The quality evaluation and summary analysis of the included literature were performed.
A total of 17 literatures were included, involving 7 systematic reviews/meta-analysis and 10 pharmacoeconomic studies. In terms of effectiveness, palonosetron had obvious advantages in the complete control rate of CINV in acute phases, delay phases and overall phases compared with the first generation 5-hydroxytryptamine 3 receptor antagonist (5-HT3RA). In terms of safety, there was no statistical significance in the incidence of common adverse reaction between palonosetron and other 5-HT3RA (P>0.05). Pharmacoeconomic studies showed that the efficacy of palonosetron was higher than other 5-HT3RA, but the cost was higher as well. It was necessary to compare the threshold of willingness to pay to determine its economy.
Palonosetron has good efficacy and safety in preventing CINV, but the economy needs to be further verified.
To analyze the effects of Wenshen Jiedu decoction combined with compound α-ketoacid tablets on renal deficiency and blood stasis type diabetic nephropathy (DN), and its effects on serum hepatocyte growth factor (HGF), thrombin-activatable fibrinolysis inhibitor (TAFI) and interleukin (IL)-21 levels.
A total of 160 DN patients with renal deficiency and blood stasis admitted to the department of nephrology, Shangqiu hospital of traditional Chinese medicine (TCM) from January 2020 to January 2022 were selected and divided into control group and experimental group according to random number table method, with 80 cases in each group. Both groups were given captopril orally under the precondition of controlling blood glucose, the control group was given compound α-ketoacid tablets, and the experimental group was given Wenshen Jiedu decoction on the basis of the control group. After 3 months continuous treatment, the efficacy and the occurrence of adverse reactions were evaluated, and the TCM syndrome scores, fasting blood glucose (FBG), 2-hour postprandial blood glucose (2hPG), glycosylated hemoglobin (HbA1c), 24-hour urinary protein excretion rate (24hUAER), serum creatinine (Scr), esti mated glomerular filtration rate (eGFR), serum HGF, TAFI and IL-21 before and after treatment were analyzed in both groups.
The total effective rate of experimental group was higher than that of control group (91.25% vs 80.00%, P<0.05). The scores of TCM syndromes in experimental group were lower than those in control group after 1 month and 3 months of treatment (P<0.05). The levels of FBG, 2hPG, HbA1c, 24hUAER, Scr, eGFR and serum HGF, TAFI and IL-21 in both groups were significantly improved, and the improvements in experimental group were more significant (P<0.05).
Wenshen Jiedu decoction combined with compound α-ketoacid tablet can effectively regulate serum HGF, TAFI and IL-21 levels, control blood glucose and improve renal function in DN patients with renal deficiency and blood stasis, with good efficacy and safety.
To explore the clinical effects of levosimendan on children requiring veno-arterial extracorporeal membrane oxygenation (VA-ECMO) after cardiac surgery.
Children who underwent cardiac surgery in the department of pediatrics, Dazu district people's hospital of Chongqing from January 2016 to October 2021, and needed VA-ECMO support after surgery and tried to quit ECMO were selected and were divided into levosimendan group (n=43) and control group (n=52). Dual robust estimation method was used to balance study covariates, including baseline characteristics, vasoactive inotropic score (VIS), the risk adjustment in congenital heart surgery-1 method (RACHS-1), and further adjustment of the final model according to the duration of ECMO. Kaplan-Meier method was used to estimate the survival rate 30 days after intubation, and log-rank test was performed.
The duration of ECMO operation in levosimendan group was longer than that in control group, and the difference was statistically significant (P<0.001). The offline failure rates of levosimendan group and control group were 4.65% and 21.15%, respectively, and the difference was statistically significant (P<0.05). After regression adjustment for ECMO duration, the levosimendan group had a lower risk of offline failure [adjusted relative risk (95% confidence interval): 0.20 (0.07 to 0.57)] and a lower risk of hospitalization death [adjusted relative risk (95% confidence interval): 0.45 (0.26 to 0.76)] than the control group. Kaplan-Meier survival curve showed that the 30-day survival rate of levosimendan group was higher than that of control group (88.37% vs 65.38%, P<0.001).
Levosimendan therapy can reduce the risk of off-line failure and in-hospital mortality in children requiring VA-ECMO after cardiac surgery.
To evaluate the efficacy and safety of nafamostat mesylate as an anticoagulant regimen in maintenance hemodialysis (MHD).
30 patients with high risk of bleeding in the department of nephrology, Shanghai fourth people's hospital were selected as the observation group, receiving the anticoagulant regimen of nafamostat mesylate, and 30 patients with MHD were selected as the control group, receiving the anticoagulant regimen of ordinary heparin. Blood routine, liver and kidney function, blood lipid status, compression hemostasis time of arterial puncture point, and activated partial thromboplastin time (APTT), prothrombin time (PT) and thrombin time (TT) in vitro and in vivo were observed before and after MHD in the two groups.
The levels of blood urea and creatinine after MHD in both groups were significantly lower than those before dialysis (P<0.05). In the observation group, APTT index in vivo was not significantly prolonged after HD, but APTT index in vitro was significantly prolonged (P<0.05). In the control group, APTT and TT index in vivo and in vitro were significantly prolonged (P<0.05). In terms of mechanical coagulation observation, the compression hemostasis time of MHD artery puncture in the observation group was significantly shorter than that in the control group (P<0.05).
Nafamostat mesylate is a safe and effective anticoagulant regimen for MHD patients at high risk of bleeding.
To evaluate the optimization effects of ciprofol combined with alfentanil for painless gastroscopy in patients with diabetes mellitus (DM).
A total of 88 DM patients who underwent painless gastroscopy in the first affiliated hospital of Zhengzhou university were enrolled and randomly divided into ciprofol combined with alfentanil group (group C) and propofol combined with alfentanil group (group P) by random number table method, with 44 cases in each group. Group C received intravenous injection of alfentanil and ciprofol, and group P received intravenous injection of alfentanil and propofol. The success rate of sedation, duration of sedation onset, time to recovery, time to discharge, incidence of adverse events, and satisfaction of anesthesiologists, endoscopists, and patients were recorded.
The incidence of bradycardia, hypotension, respiratory depression and injection pain in group P was lower than that in group C (22.73% vs 9.09%, 56.89% vs 20.45%, 38.64% vs 6.82%, 59.09% vs 4.55%, P<0.05). Compared with group C, the anesthesiologists and patients satisfaction in group P increased [(6.82±0.80) vs (8.03±0.60), (8.82±0.70) vs (9.44±1.20), (P<0.05)].
Compared with conventional anesthesia, ciprofol combined with alfentanil can optimize the safety and effectiveness of painless gastroscopy in DM patients.
To explore the clinical effects of Banxia Xiexin decoction combined with zopiclone tablets in the treatment of perimenopausal insomnia patients with phlegm-fire disturbing heart syndrome.
A total of 150 perimenopausal insomnia patients with phlegm-fire disturbing heart syndrome in our hospital were selected and divided into observation group and control group by random number table method, 75 cases in each group. The control group was treated with zopiclone tablets, and the observation group was treated with Banxia Xiexin decoction combined with zopiclone tablets. After treatment, the total effective rate of the two groups was compared. The score of Pittsburgh sleep quality index scale and traditional Chinese medicine syndrome score were observed. The laboratory examination indicators and adverse reactions before and after treatment were compared between the two groups.
After 4 weeks of treatment, the total effective rate of the observation group was 95.89% (70/73) higher than that of the control group 81.94% (59/72, χ2=7.181, P=0.007). After 2 and 4 weeks of treatment, the Pittsburgh sleep quality index score, traditional Chinese medicine syndrome score, serum follicle stimulant hormone, malondialdehyde, peptide and α-amylase in observation group were lower than those in control group, and glutathione peroxidase was higher than that in control group (P<0.05). There was no significant difference in adverse reactions between the two groups (χ2=0.280, P=0.597).
Banxia Xiexin decoction combined with zopiclonone tablet has good efficacy and safety in the treatment of perimenopausal insomnia patients with phlegm fire disturbing heart syndrome. It can effectively regulate the activity of sex hormone and sympathetic nerve, reduce the level of oxidative stress, improve sleep quality.
To evaluate the efficacy and safety of third-line treatment of duvarizumab combined with apatinib in the treatment of unresectable advanced colorectal cancer (CRC).
Sixty-six unresectable advanced CRC patients who received combination therapy (combination group, n=30) or apatinib monotherapy (monotherapy group, n=36) as third-line treatment were included. All patients were treated until intolerance or disease progression. The overall treatment response, objective response rate, disease control rate and incidence of adverse events were compared between the two groups.
The overall response in the combination group was higher than that of the monotherapy group (P=0.025). The rates of complete response, partial response, stable disease, and disease progression in the combination group were 0, 26.67%, 50.00%, and 23.33%, respectively. Meanwhile, those in the monotherapy group were 0, 8.33%, 47.23%, and 44.44%, respectively. The objective response rate in the combination group was higher than that in the monotherapy group (26.67% vs 8.33%, P=0.047), but the difference was not statistically significant in disease control rate between the two groups (76.67% vs 55.56%, P=0.073). The progression-free survival (median: 8.60 months vs 4.50 months, P=0.012) and overall survival (median: 15.70 months vs 8.10 months, P=0.009) of combination group were superior to those of the monotherapy group. The incidence of adverse events in the combination group was similar to that in the monotherapy group (P>0.05). Most adverse events in the combination group were grade 1 - 2, and only 7 patients (23.33%) had grade 3 - 4 adverse events.
Third-line treatment of duvaliuzumab combined with apatinib could improve the response rate and prolong survival in patients with unresectable advanced CRC with an acceptable safety profile.
To investigate the effect of neoadjuvant chemotherapy combined with mannitol enema on R0 resection rate of locally advanced rectal cancer (LARC).
A total of 90 patients with LARC admitted to the first affiliated hospital of Hebei north hospital from June 2015 to June 2019 were selected and divided into control group (neoadjuvant chemotherapy+radical operation) and the intervention group (neoadjuvant chemotherapy+mannitol enema+radical operation). The relevant indicators before treatment, before operation and after operation were observed and recorded, and statistical analysis was performed.
The R0 resection rate of the intervention group was significantly higher than that of the control group, while the operative time and intraoperative blood loss were significantly lower than those of the control group, and the differences were statistically significant (P<0.05). The rate of anastomotic bleeding and tumor recurrence in the intervention group were significantly lower than those in the control group, and the differences were statistically significant (P<0.05).
Neoadjuvant chemotherapy combined with mannitol enema can increase the R0 resection rate of LARC, decrease the operation time, reduce the postoperative complications and tumor recurrence, which is beneficial to the prognosis of patients and worthy of clinical promotion.
To explore the clinical effects of Yangxin Shengmai granules in the treatment of ischemic heart failure (IHF) caused by Qi deficiency and blood stasis, and its effect on cardiac function, serum S100 calcium-binding protein A8/A9 complex (S100A8/A9), nuclear factor (NF)-κB, receptor of advanced glycation end-product (RAGE) and high mobility group protein (HMG) B1 levels.
A total of 102 patients with IHF admitted to the department of cardiology of our hospital from March 2017 to March 2019 were selected as the study objects and divided into control group (conventional western medicine treatment) and observation group (conventional western medicine treatment+Yangxin Shengmai granules), with 51 cases in each group. The course of treatment was 3 months. Clinical efficacy and drug safety of the two groups were observed, and traditional Chinese medicine (TCM) syndrome score, 6 minute walking test (6MWT), Minnesota living with heart failure questionnaire (MLHF-Q) score, cardiac output (CO), left ventricular ejection fraction (LVEF), left ventricular end-systolic diameter (LVESD), left ventricular end-diastolic diameter (LVEDD), heart rate variability (HRV) parameters, plasma brain natriuretic peptide (BNP), serum S100A8/A9, NF-κB, RAGE and HMGB1 levels were compared between the two groups.
The total effective rate of observation group was higher than that of control group (94.12% vs 80.39%, P<0.05). The TCM syndrome score and MLHF-Q score of the observation group were lower than those of the control group, and the 6MWT score was higher than that of the control group (P<0.05). The LVEF, CO and HRV parameters of the observation group were higher than those of the control group, and the levels of LVESD, LVEDD and plasma BNP were lower than those of the control group (P<0.05). Serum levels of S100A8/A9, NF-κB, RAGE and HMGB1 in observation group were lower than those in control group (P<0.05). There was no significant difference in the incidence of adverse reactions between the two groups (7.84% vs 9.80%, P>0.05).
Yangxin Shengmai granules has a significant effect on IHF of Qi deficiency and blood stasis, which can effectively improve clinical symptoms, cardiac function and quality of life, delay ventricular remodeling process to a certain extent, and improve serum levels of S100A8/A9, NF-κB, RAGE and HMGB1.
To investigate the effect of febuxostat combined with hemodialysis in the treatment of chronic kidney disease (CKD) and its effect on fibroblast growth factor (FGF) 23 and bone metabolism.
A total of 105 patients with CKD who treated at the department of nephrology in our hospital from February 2020 to February 2021 were selected and divided into experimental group (n=53, hemodialysis+febuxostat) and control group (n=52, hemodialysis) by random number table method. The clinical efficacy, serum FGF23, serum uric acid, serum calcium, blood phosphorus, parathyroid hormone (PTH), serum creatinine (Scr), blood urea nitrogen (BUN) and occurrence of adverse reactions were compared between the two groups.
After treatment, there was a statistically significant difference in the total effective rate between the control group and the experimental group (51.92% vs 81.13%, P<0.05), but no statistically significant difference in the incidence of adverse reactions (9.43% vs 19.23%, P>0.05). The levels of serum FGF23, blood uric acid, blood phosphorus, PTH, Scr and BUN in both groups were decreased with time, and the experimental group were lower than those in the control group, the differences were statistically significant (P<0.05). The serum calcium level of both groups increased with time, and the experimental group was higher than that in the control group, the difference was statistically significant (P<0.05). Serum FGF23 and blood uric acid were positively correlated with blood phosphorus, PTH, Scr and BUN (P<0.05), and negatively correlated with blood calcium (P<0.05).
Febuxostat combined with hemodialysis has a significant effect in patients with CKD, which can effectively improve serum FGF23 and bone metabolism, with good safety.
Roxadustat is a new hypoxia-inducible factor prolyl hydroxylase inhibitor. It could effectively alleviate anemia symptoms and increase the level of hemoglobin in dialysis and non-dialysis patients with chronic kidney disease anemia, with no inferior or even superior efficacy to erythropoietin stimulating agents. Roxadustat has been marketed in China, Japan and some many European countries, whereas its safety issues such as adverse drug reactions and drug interactions deserve attention. This paper reviewed the research progress and clinical application of roxadustat, so as to provide reference for its further development and rational use.
To compare the cost and effectiveness of fractional flow reserve (FFR) combined with coronary angiography (CAG) versus CAG alone in guiding the diagnosis and treatment of coronary atherosclerotic heart disease from the perspective of China's medical and health system.
The evaluation model of health economics (short-term decision tree plus long-term Markov model) was constructed. The length of each cycle of the model was 1 year, and the simulation period was 10 years. The model was used to compare the difference in the degree of coronary stenosis between FFR combined with CAG group (FFR group) and CAG group. The difference in the composition of the treatment methods of the two groups were analyzed and the cost-effectiveness was measured.
The overall cost of FFR group was 109 434 Yuan, and the corresponding effect was 7.75 quality adjusted life years (QALYs). The overall cost of CAG group was 120 722 Yuan, and the corresponding effect was 7.65 QALYs. Compared with CAG group, the incremental cost-effectiveness ratio of FFR group was -112 460 Yuan/QALYs.
FFR group is more cost-effective than CAG group. The advantage of FFR group comes from the accurate diagnosis of coronary functional lesions to help doctors accurately determine the degree of stenosis and treatment methods, avoid unnecessary percutaneous coronary intervention surgery and stent implantation, improve the quality of life of patients, and reduce the medical cost of complications.
In recent years, the number of rare dise ase drugs included in the national medical insurance negotiation list has been increased, and the landing of rare disease drugs in National Negotiation Drugs is the key to evaluate the effect of the policy. Based on the online drug procurement data of medical institutions in Hubei province from January 2018 to December 2022, this article conducted a study on rare disease drugs that had been negotiated four times between 2017 and 2021. Defined daily doses (DDDs), defined daily dose cost and procurement amount were selected to compare before and after the policy, and catastrophic health expenditure indicators were used to evaluate the affordability of rare disease drugs. The analysis revealed that among the 21 negotiated rare disease drugs, 5 drugs were not procured by medical institutions in Hubei province from 2017 - 2021. Compared with 2018, the DDDs and procurement amount decreased in 2019, but the DDDs and amount of negotiated rare disease drugs increased year by year from 2020 to 2022. Before reimbursement by medical insurance, there were 14 and 15 drugs with annual treatment costs exceeding catastrophic health expenditures for urban and rural residents, respectively. After reimbursement by employee medical insurance, there were 7 and 10 drugs with annual treatment costs exceeding catastrophic health expenditures for urban and rural residents, respectively. There were 10 and 13 drugs after reimbursement by residents' medical insurance, respectively. Therefore, it is suggested that the government should take lead improving the multi-party co-payment for rare disease drugs and achieve classified management for the extremely poor population, so as to consolidate the guarantee of people's livelihood.